Clinical Pharmacokinetics in Patients with Burns

Clinical Pharmacokinetics

Volumn 29, Issue 1, 1995, Pages 15-28

  Jaehde, Ulrich ^a   Sörgel, Fritz ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTIULCER AGENT; ANXIOLYTIC AGENT; AZTREONAM; BETA LACTAM; CEFTAZIDIME; CIMETIDINE; CREATININE; CYCLOSPORIN; DIAZEPAM; GLYCOPEPTIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; IMIPRAMINE; LACTULOSE; LIDOCAINE; MUSCLE RELAXANT AGENT; OROSOMUCOID; PENTOBARBITAL; PETHIDINE; PHENYTOIN; PIPERACILLIN; PROPRANOLOL DERIVATIVE; QUINOLONE; SALICYLIC ACID; TICARCILLIN; UNINDEXED DRUG;

BURN; CREATININE CLEARANCE; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXTRACELLULAR SPACE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERMETABOLISM; IMMUNE RESPONSE; LIVER BLOOD FLOW; LIVER CLEARANCE; MOLECULAR WEIGHT; NONHUMAN; PAIN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ABSORPTION; ANALGESICS; ANTI-ANXIETY AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BURNS; HALF-LIFE; HUMAN; METABOLIC CLEARANCE RATE; NEUROMUSCULAR AGENTS; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 0029031317     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199529010-00003     Document Type: Review

References (75)

1. Hospital care of major burns
2. Pathophysiology and pharmacokinetics following burn injury
3. Drug kinetics in burn patients
4. Burns
5. Clinical pharmacology and drug therapy in the burned patient
6. Effect of penicillin G on Staphylococcus aureus phagocytosed by human monocytes
7. Increased intestinal permeability associated with infection in burn patients
8. Intestinal permeability is increased in burn patients shortly after injury
9. Increased gut permeability early after burns correlates with the extent of burn injury
10. Cutaneous thermal injury alters macromolecular permeability of rat small intestine
11. Increased gut permeability following burn trauma
12. Increased transcellular permeability of rat small intestine after thermal injury
13. Alterations in intestinal permeability after thermal injury
14. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens
15. Plasma protein binding of drugs after severe burn injury
16. Postburn serum drug binding and serum protein concentrations
17. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients
18. Studies of renal function during the early postburn period
19. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin
20. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
21. Effect of injury and infection on visceral metabolism and circulation
22. Urinary excretion of D-glucaric acid by severely burned patients
23. The effect of thermal injury on drug metabolism in the rat
24. Pharmacokinetics of pentobarbital, quinidine, lidocaine, and theophylline in the thermally injured rat
25. Aztreonam pharmacokinetics in burn patients
26. Imipenem pharmacokinetics in patients with burns
27. Thermal injury effects on drug disposition: a prospective study with piperacillin
28. Pharmacokinetics of ticarcillin/clavulanate in severely burned patients
29. The necessity of increased doses of amikacin in burn patients
30. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients
31. Pharmacokinetics of ciprofloxacin in patients with burn injuries
32. Pharmacokinetics of teicoplanin in burn patients
33. Altered vancomycin dose vs. serum concentration relationship in burn patients
34. Physiological disposition of macrolides
35. Pharmacokinetic disposition of quinolones in human body fluids and tissues
36. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury
37. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam
38. Kinetic model for gentamicin dosing with the use of individual patient parameters
39. Increased dosing requirements for amikacin in burned children
40. Initial dosage regimens of gentamicin in patients with burns
41. Brief report: gastrointestinal secretion of ciprofloxacin
42. Pharmacokinetics of gyrase inhibitors, part 1: basic chemistry and gastrointestinal disposition
43. Pharmacokinetics of gyrase inhibitors, part 2: renal and hepatic elimination pathways and drug interactions
44. Vancomycin elimination in patients with burn injury
45. Pharmacokinetics of teicoplanin in hemodialysis patients
46. Burns
47. Cimetidine kinetics during resuscitation from burn shock
48. Increased cimetidine clearance in burn patients
49. Pharmacokinetics and pharmacokinetics of ranitidine after burn injury
50. Disposition of alfentanil in burns patients
51. Pharmacokinetics of continous intravenous infusion of methadone in the early post-burn period
52. Morphine pharmacokinetics during anesthesia and surgery in patients with burns
53. Meperidine disposition in burn patients
54. Effect of thermal injury on the pharmacokinetics of atracurium in humans
55. Pharmacokinetics of d-tubocurarine in patients with thermal injury
56. Elevated plasma binding cannot account for the burn-related d-tubocurarine hyposensitivity
57. Diazepam kinetics in patients with severe burns
58. Lorazepam conjugation is unimpaired in burn trauma
59. Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children
60. Management of pain during debridement survey in U.S. burn units
61. Analgesia and morphine disposition in burn patients
62. Long term high dose morphine, ketamine and midazolam infusion in a child with burns
63. Clinical pharmacology of muscle relaxants in patients with burns
64. Increased d-tubocurarine requirement following major thermal injury
65. Burn injury to rat increases nicotinic acetylcholine receptors in the diaphragm
66. Succinylcholine-induced hyperkalemia in burned patients, 1
67. Delayed clearance of diazepam due to cimetidine
68. Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients
69. Cyclosporine A for prolonging allograft survival in patients with massive burns
70. Marked increase in plasma interleukin-6 in burn patients
71. Population pharmacokinetics: theory and clinical application
72. Population pharmacokinetics